Exploratory Study on the Safety and Efficacy of Disitamab Vedotin in Combination with Anlotinib Hydrochloride for the Treatment of HER-2-expressing Recurrent Platinum-resistant Ovarian Cancer.

Ovarian cancer is one of the three major malignant tumors of the female reproductive system. Even if newly diagnosed ovarian cancer patients undergo ideal tumor cell reduction surgery and postoperative chemotherapy, 70% to 80% of ovarian cancer patients still experience recurrence. According to the length of PFI (platinum free interval), recurrent ovarian cancer (ROC) can be classified into platinum resistant ROC (\<6 months) and platinum sensitive ROC (\>6 months). There is currently no optimal treatment plan for platinum resistant ovarian cancer (PROC), and the prognosis for patients is poor

Trial Details

NCT ID

NCT06660511

Phase

EARLY_PHASE1

Sponsor

Second Xiangya Hospital of Central South University

Status

RECRUITING

Cancer Type

Ovarian Cancer

Interventions

Disitamab Vedotin in Combination With Anlotinib Hydrochloride

Locations (sample)

Changsha, Hunan, China|28.19874,112.97087

Key Eligibility Criteria

The subjects voluntarily joined this study, signed an informed consent form, and showed good compliance;
Age ≥ 18 years old when signing the informed consent form;
Epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer diagnosed by organizational or cellular pathology;
The subjects can provide tumor primary or metastatic site specimens for HER2 detection (paraffin blocks, paraffin embedded sections, or fresh tissu…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Ovarian Cancer Trials on Trialify →